The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://amp.dw.com/en/new-german-covid-19-rules-come-into-force-as-infections-rise-in-colder-months/a-63305695
We have, as of end of September, abandoned asymptomatic testing of NHS staff and patients. These and other measures including N95 mask wearing introduced in Germany on the evidence of Autumn wave starting introduced the very next day. The irony of this is painful and a little terrifying. UK is flying blind once again when others are sharpening their defences.
I’m certainly up for that. It would require a little work to pull together all the relevant data but it is all listed as RNSs on Synairgen ‘s website. A back of the envelope pulling of at home and A2P2 data and pooling of phase 2 and Sprinter needed. Summary of exploratory subgroup analysis from recent RNSs too.
Who knows it could get a parliamentary question perhaps from the right honorable MP for Southampton.
The meta-analysis to be properly done would need Synairgen to support in the form of individual patient level data.
https://www.ecdc.europa.eu/en/publications-data/download-data-hospital-and-icu-admission-rates-and-current-occupancy-covid-19
This is probably the best source of reliable data from Europe.
This is great news and nice work. The populations of participants look broadly similar- within 7 days of symptom onset. Pooling likely therefore valid. We would need to see the data on participant details but that will come.
I’m surprised SP response so muted. It’s still well below level when last good news broke! Such is market sentiment at the moment. The greater question is who would sell with market valuations at these levels- sub £40. The potential market is huge. Paxlovid data is for
Answer to chi-sq question. It comes down to stats. Chi-sq used for categorical variables. It’s a no-nonsense test and tells me they didn’t use any statistical jiggery pokery to find the statistically significant results.
I may be wrong but I think that one issue for the big orders was that ITM didn’t have the 5 mw electrolyser up and going. I was slightly disconcerted when ITM got a £9m grant 3-4 months ago to develop this. Looks like strategically they should have had this totally sorted before massive upscale of capacity. Once it is proven I’m hoping some bigger orders will come. Meantime hold and hope.
Possible takeover target?
https://hydrogen-central.com/linde-build-35-megawatt-pem-proton-exchange-membrane-electrolyzer-produce-green-hydrogen-niagara-falls-new-york/
Surely this will be ITM supplying the electrolyser. Modest scale but hopefully a signal of confidence.
My view of this is that is really raising the profile of synairgen and treatment of acute respiratory viral infections generally. It won’t support EUA or full authorisation but may help better define the scale of the problem.
Certainly good to be involved with but not a game changer. Potentially another building block in the scientific base though and good publicity.
Neon- I agree.
I’m perplexed why uk and European governments are so behind the curve on this. It was evident from the very first day of Ukraine invasion that governments should be on an energy war footing and actively sourcing and scaling green hydrogen/renewables on a massive scale.
The low hanging fruit is immediate scaling of green H2 and replacing all ammonia products and all other industrial processes that currently use grey H2 with green. Other relatively easy action is green H2 blend in heating.
We are nowhere near where we could have been in terms of green H2 displacing grey.
Probably a trillion euros across Europe supporting people to pay inflated gas/energy prices this year alone that could have been better spent on immediate rapid upscale of green H2 and reducing gas demand.
Dr Eric Fiegel-Ding might be useful to follow for updates on this story.
https://twitter.com/drericding/status/1565412571385139202?s=21&t=TeK3XhzUXygHHUHtubktyg
I’m with you Mr Costs. All the evidence points to SNG being really very effective. Virus and variant agnostic. Possibly even working in combination with other therapies. I will just need to be patient. Playing the ups and downs of sentiment very high risk strategy. Board is at its best when digging out research and evidence.
My best memory from this board was the good Dr from Kansas who slipped up and let news of progression to P3 out of the bag. It took 3-4 months from then to get confirmation. ACTIV2 results seem to be similarly slow. They may help point to where SNG is best targeted. I recall SHH saying that he thought best targeted in very high risk populations to prevent admission. ACTIV2 may support that. I’m all in and staying in.
I can’t find any mention of anything either. Hopefully just market sentiment/wobble.
Interesting. Amazon have taken option for 16 million shares. First 9 million at just under $23 and then next 7million at 90% of weighted average of 30 days.
At first sight looks like plug giving away significant part of their company to secure the deal. In essence Amazon taking 3% stake ($480 million) at a 10-30% discount on a $2.1 billion deal. I suppose like all deals they both must see this as having something in it for them.
I too have plug shares also (interest declared). I think the model of electrolyser supply being tied to H2 supply agreement and possibly other supply agreements is very interesting and is something ITM and Linde could really learn from. Perhaps the Hydrogen train Linde H2 supply detailed in other thread is an example.
Hopefully more to come for ITM and greater scale. The relationships have already been established to facilitate this. It was these relationships that made me invest in ITM in the first place. I would like to see them bear more fruit.
Surely this will be ITM?
Linde sourcing green hydrogen locally in Lower Saxony within 3 years.
https://www.independent.co.uk/news/lower-saxony-ap-fleet-germany-berlin-b2151701.html?amp